A new market research report from MarketsandMarkets projects steady growth for patient-derived xenograft (PDX) models across the rest of Latin America through 2030. The study, released on August 3, 2026, highlights the region's expanding role in preclinical cancer research, driven by increasing investments in personalized medicine and biotech innovation.

Why Latin America Emerges as a Key PDX Hub

The rest of Latin America—covering countries beyond the primary markets like Brazil and Mexico—is gaining traction as a cost-effective and biologically diverse region for PDX model development. These models, which involve implanting patient tumor tissue into immunodeficient mice, are crucial for testing drug efficacy and guiding personalized treatment strategies.

According to the report, factors such as improving research infrastructure, growing public-private partnerships, and a rising prevalence of cancer are fueling demand. Additionally, the region's unique genetic diversity offers valuable insights for drug development targeting underserved populations.

Market Drivers and Opportunities

  • Rising cancer burden: Increasing incidence rates across Latin America necessitate more effective preclinical models.
  • Cost advantages: Lower operational costs compared to North America and Europe attract international pharma outsourcing.
  • Regulatory progress: Streamlined ethical guidelines for animal research are encouraging more academic and commercial projects.

Challenges and Restraints in the Regional Market

Despite the optimistic outlook, the market faces hurdles, including limited funding for advanced research in some countries, a shortage of specialized personnel, and logistical complexities in transporting biospecimens across borders. The report notes that these constraints may temper growth in the near term, but ongoing capacity-building efforts are expected to mitigate them.

Key Players and Collaborative Trends

International pharmaceutical companies and CROs are increasingly partnering with local academic institutions to establish PDX banks and biorepositories. These collaborations are vital for standardizing protocols and ensuring quality control, which remains a critical challenge in the region. The report emphasizes that such alliances will be instrumental in unlocking the full potential of the market.

Forecast and Strategic Outlook

The MarketsandMarkets analysis projects a compound annual growth rate (CAGR) for the rest of Latin America PDX models market over the 2025-2030 period, though specific figures were not disclosed in the summary. The growth trajectory is supported by an uptick in oncology research funding and the adoption of advanced technologies like CRISPR and organoid models alongside traditional PDX.

For stakeholders, the key takeaway is the region's strategic importance as a complement to established markets. Companies that invest early in local partnerships and infrastructure stand to gain a competitive edge in the global PDX landscape.

Key Takeaways

  • The rest of Latin America PDX market is set for steady expansion through 2030, driven by cancer research needs and cost efficiency.
  • Collaboration between international pharma and regional researchers is essential to overcome infrastructure gaps.
  • Despite challenges, the region offers unique genetic diversity that can enhance drug development pipelines.

For a comprehensive breakdown, including market segmentation and competitive analysis, the full report is available from MarketsandMarkets.